Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Go back to Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
(NASDAQ: RZLT) Delayed: 3.86 --0 (-0%)
Previous Close $3.86    52 Week High $ 
Open $3.78    52 Week Low $ 
Day High $3.94    P/E N/A 
Day Low $3.70    EPS $ 
Volume 1,198,115